Technical Analysis for VERU - Veru Inc.

Grade Last Price % Change Price Change
grade C 1.38 1.47% 0.02
VERU closed up 1.47 percent on Tuesday, January 15, 2019, on 82 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical VERU trend table...

Date Alert Name Type % Chg
Jan 15 20 DMA Resistance Bearish 0.00%
Jan 15 50 DMA Resistance Bearish 0.00%
Jan 15 Calm After Storm Range Contraction 0.00%
Jan 15 Inside Day Range Contraction 0.00%
Jan 14 Fell Below 20 DMA Bearish 1.47%
Jan 14 Fell Below 50 DMA Bearish 1.47%
Jan 14 Outside Day Range Expansion 1.47%
Jan 14 Upper Bollinger Band Touch Strength 1.47%
Jan 14 Down 3 Days in a Row Weakness 1.47%
Jan 14 Down 4 Days in a Row Weakness 1.47%

Older signals for VERU ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Veru Inc., a medical therapeutics company, develops, manufactures, and markets consumer health care products. The company’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus. The company primarily serves global agencies, non-government organizations, ministries of health, and other governmental agencies directly, as well as through distribution agreements and other arrangements with commercial partners. It has operations in the United States, Brazil, Zimbabwe, South Africa, Angola, the Democratic Republic of the Congo, Tanzania, Malaysia, Spain, France, the United Kingdom, and internationally. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Is VERU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.37
52 Week Low 1.17
Average Volume 84,658
200-Day Moving Average 1.7364
50-Day Moving Average 1.4015
20-Day Moving Average 1.3878
10-Day Moving Average 1.4195
Average True Range 0.1018
ADX 20.15
+DI 27.49
-DI 13.3549
Chandelier Exit (Long, 3 ATRs ) 1.3446
Chandelier Exit (Short, 3 ATRs ) 1.5754
Upper Bollinger Band 1.5153
Lower Bollinger Band 1.2603
Percent B (%b) 0.47
BandWidth 18.374406
MACD Line 0.0037
MACD Signal Line 0.003
MACD Histogram 0.0007
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.49
Resistance 3 (R3) 1.49 1.46 1.47
Resistance 2 (R2) 1.46 1.43 1.46 1.46
Resistance 1 (R1) 1.42 1.42 1.44 1.42 1.46
Pivot Point 1.39 1.39 1.40 1.39 1.39
Support 1 (S1) 1.35 1.36 1.37 1.35 1.30
Support 2 (S2) 1.32 1.35 1.32 1.30
Support 3 (S3) 1.28 1.32 1.29
Support 4 (S4) 1.28